Investigating new treatments for non-small cell lung cancer using SHP2 inhibitors
Response and resistance to SHP2 inhibitors alone and in combination in Non-Small Cell Lung Cancer
This study is looking at new ways to treat advanced non-small cell lung cancer by testing a medication that blocks certain signals in cancer cells, especially for patients with specific gene changes or those who haven't responded to other treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10993090 on NIH RePORTER |
What this research studies
This research focuses on developing new therapeutic strategies for metastatic non-small cell lung cancer (NSCLC) by exploring the use of SHP2 inhibitors, which are designed to block specific cancer cell signaling pathways. The study aims to understand how these inhibitors can work alone or in combination with other treatments, particularly in patients with KRAS mutations or those resistant to existing therapies. By conducting clinical trials, the research will evaluate the effectiveness of these inhibitors in enhancing cancer treatment outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with metastatic non-small cell lung cancer, particularly those with KRAS mutations or who have shown resistance to current therapies.
Not a fit: Patients with early-stage non-small cell lung cancer or those who do not have KRAS mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with advanced non-small cell lung cancer.
How similar studies have performed: Other research has shown promising results with similar approaches using targeted therapies in cancer treatment, indicating potential for success in this area.
Where this research is happening
New York, United States
- New York University School of Medicine — New York, United States (Active)
Researchers
- Principal investigator: Neel, Benjamin G. — New York University School of Medicine
- Study coordinator: Neel, Benjamin G.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.